Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients.
Colin de Verdiere N, Durier C, Samri A, Meiffredy V, Launay O, Matheron S, Mercier-Delarue S, Even S, Aboulker JP, Molina JM, Autran B, Simon F; ANRS EP46 NOVAA Group. Colin de Verdiere N, et al. AIDS. 2018 Oct 23;32(16):2291-2299. doi: 10.1097/QAD.0000000000001963. AIDS. 2018. PMID: 30096071
Rheumatic manifestations caused by tropical viruses.
Colin de Verdière N, Molina JM. Colin de Verdière N, et al. Joint Bone Spine. 2007 Oct;74(5):410-3. doi: 10.1016/j.jbspin.2006.11.019. Epub 2007 May 30. Joint Bone Spine. 2007. PMID: 17613266 No abstract available.
HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.
Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Bénard A, Campa P, Chêne G, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2). Roquebert B, et al. J Antimicrob Chemother. 2008 Nov;62(5):914-20. doi: 10.1093/jac/dkn335. Epub 2008 Aug 20. J Antimicrob Chemother. 2008. PMID: 18718922
Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial.
Launay O, van der Vliet D, Rosenberg AR, Michel ML, Piroth L, Rey D, Colin de Verdière N, Slama L, Martin K, Lortholary O, Carrat F; ANRS HB03 VIHVAC-B Trial. Launay O, et al. Among authors: colin de verdiere n. JAMA. 2011 Apr 13;305(14):1432-40. doi: 10.1001/jama.2011.351. JAMA. 2011. PMID: 21486976 Clinical Trial.
Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial.
Launay O, Desaint C, Durier C, Loulergue P, Duval X, Jacomet C, Pialoux G, Ghosn J, Raffi F, Rey D, Ajana F, Colin de Verdière N, Reynes J, Foubert V, Roman F, Devaster JM, Delfraissy JF, Aboulker JP; ANRS 151 HIFLUVAC Study Group and the French Clinical Vaccinology Network (Réseau National d'Investigation Clinique en Vaccinologie REIVAC). Launay O, et al. Among authors: colin de verdiere n. J Infect Dis. 2011 Jul 1;204(1):124-34. doi: 10.1093/infdis/jir211. J Infect Dis. 2011. PMID: 21628666 Free PMC article. Clinical Trial.
Molecular characterization of the 17D-204 yellow fever vaccine.
Salmona M, Gazaignes S, Mercier-Delarue S, Garnier F, Korimbocus J, Colin de Verdière N, LeGoff J, Roques P, Simon F. Salmona M, et al. Among authors: colin de verdiere n. Vaccine. 2015 Oct 5;33(41):5432-5436. doi: 10.1016/j.vaccine.2015.08.055. Epub 2015 Aug 24. Vaccine. 2015. PMID: 26314624
The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial.
Dinges W, Girard PM, Podzamczer D, Brockmeyer NH, García F, Harrer T, Lelievre JD, Frank I, Colin De Verdière N, Yeni GP, Ortega Gonzalez E, Rubio R, Clotet Sala B, DeJesus E, Pérez-Elias MJ, Launay O, Pialoux G, Slim J, Weiss L, Bouchaud O, Felizarta F, Meurer A, Raffi F, Esser S, Katlama C, Koletar SL, Mounzer K, Swindells S, Baxter JD, Schneider S, Chas J, Molina JM, Koutsoukos M, Collard A, Bourguignon P, Roman F. Dinges W, et al. Among authors: colin de verdiere n. Medicine (Baltimore). 2016 Feb;95(6):e2673. doi: 10.1097/MD.0000000000002673. Medicine (Baltimore). 2016. PMID: 26871794 Free PMC article. Clinical Trial.
Screening test for neutralizing antibodies against yellow fever virus, based on a flavivirus pseudotype.
Mercier-Delarue S, Durier C, Colin de Verdière N, Poveda JD, Meiffrédy V, Fernandez Garcia MD, Lastère S, Césaire R, Manuggera JC, Molina JM, Amara A, Simon F. Mercier-Delarue S, et al. Among authors: colin de verdiere n. PLoS One. 2017 May 31;12(5):e0177882. doi: 10.1371/journal.pone.0177882. eCollection 2017. PLoS One. 2017. PMID: 28562615 Free PMC article.
Immunogenicity and Safety of Yellow Fever Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients After Withdrawal of Immunosuppressive Therapy.
Sicre de Fontbrune F, Arnaud C, Cheminant M, Boulay A, Konopacki J, Lapusan S, Robin C, Bernaudin F, Suarez F, Simon F, Socié G, Colin de Verdière N, Consigny PH. Sicre de Fontbrune F, et al. Among authors: colin de verdiere n. J Infect Dis. 2018 Jan 17;217(3):494-497. doi: 10.1093/infdis/jix564. J Infect Dis. 2018. PMID: 29087520
Hepatitis Rebound after Infection with Yellow Fever Virus.
Denis B, Chirio D, Ponscarme D, Brichler S, Colin de Verdière N, Simon F, Molina JM. Denis B, et al. Among authors: colin de verdiere n. Emerg Infect Dis. 2019 Jun;25(6):1248-1249. doi: 10.3201/eid2506.190069. Epub 2019 Jun 17. Emerg Infect Dis. 2019. PMID: 30870138 Free PMC article.
36 results